A Phase 2 interventional study of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine and Saline in Ebola, sponsored by Canadian Immunization Research Network. Completed at 1 site in Canada. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Canadian Immunization Research Network · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.
The study will enroll approximately 250 participants, \~100 at 2 sites in Canada and \~100 at 2 sites in Africa. Overall \~200 participants will receive the study vaccine and 50 will receive a placebo . Sequential enrollment of five study cohorts will occur over time at each study site according to CD4 T-cell counts: Group 1 will include adult subjects with CD4 ≥ 500 cells/mm3, Group 2 CD4 > 350 and \< 500 cells/mm3, Group 3 CD4 ≥ 200 and ≤ 350 cells/mm3, Group 4 adolescents CD4 ≥ 200 cells/mm3, and Group 5 adults and adolescents CD4 ≥ 200 cells/mm3. Enrolment and vaccine administration will begin with the group with the highest CD4 count. When the D42 post-vaccination period is completed for all subjects in Group 1, and the Data Safety Monitoring Board (DSMB) has reviewed the safety data and determined that there are no concerns, enrolment and vaccination of the next CD4 cohort may begin. Similarly, when the D42 safety data for Group 2 has been reviewed/approved by the DSMB, enrolment and vaccination of participants in Group 3 may begin. Adolescents 13-17 years of age (inclusive) with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adults with CD4 ≥ 200. Adolescents 13-17 years of age (inclusive) and adults with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adolescents with CD4 ≥ 200.Within each group, participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the study vaccine or the placebo in a ratio of 4 to 1 (160:40). Participants will complete memory aids for 42 days following vaccination.
Specific procedures to be performed during the trial, as well as their prescribed times and associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each procedure are provided in Section 7.0 - Trial Procedures.
This trial will use an adaptive design based on pre-specified criteria, using an independent, external DSMB to monitor safety and immunogenicity. There will be 3 formal safety analyses performed by the DSMB. Data for at least 75% of participants must be available for each analysis. The first safety analysis will be conducted when the first group (CD4 ≥ 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The second safety analysis will be conducted when the second group (CD4 > 350 and \< 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The third safety analysis will be conducted when the third group (Adults CD4 ≥ 200 and ≤ 350 cells/mm3) will have completed 42 days of follow-up post vaccination. The fourth safety analysis will be conducted when the fourth group (Adolescents CD4 ≥ 200) will have completed 42 days of follow-up post vaccination.
Results of the safety analysis will be reviewed by the DSMB, which will make recommendations to the Sponsor to continue, modify or end the trial according to the plan described briefly in Section 2.2 - Trial Diagram and in detail in Section 8.0 - Statistical Analysis Plan. In case of an outbreak of Ebola Zaire the DSMB may recommend to vaccinate subjects randomized to receive placebo with V920 provided at least 84 days of SAE follow-up is conducted.
104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.
This study's enrollment of 251 is above the median of 94 across 81 interventional studies indexed under Hemorrhagic Fever, Ebola.
Browse Hemorrhagic Fever, Ebola studies →Canadian Immunization Research Network is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males and females who are willing to practice abstinence from sexual intercourse, or are willing to use effective methods of , from at least 30 days prior to vaccination until 2 months after vaccination.
i. Male condoms PLUS: ii. Oral contraceptives, either combined or progestogen alone iii. injectable progestogen iv. implants of etenogestrel or levonorgestrel v. oestrogenic vaginal ring vi. percutaneous contraceptive patches vii. intrauterine device or intrauterine system
Be willing to minimize blood and body fluid exposure of others for 6 weeks after vaccination
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomly assigned to receive ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine.
Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
Participants randomly assigned to receive placebo. Saline: Normal saline (0.9%) was chosen as an inert substance to serve as placebo control.
Other: Saline
The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
Number of Participants With Solicited Adverse Events Following V920 Vaccination
The number of participants with general solicited local (at the injection site) and systemic adverse events following vaccination will be summarized. Local AES include: pain at injection site, redness at injection site, swelling at injection site Systemic AEs include: fever, arthritis, arthralgia, rash and blisters/vesicular lesions.
Time frame: From vaccine administration up to day 14 following vaccination
Number of Participants With Solicited Adverse Events Following V920 Vaccination
The number of participants with solicited systemic adverse events following vaccination that include arthralgia, blister, joint swelling, pyrexia and rash
Time frame: From vaccine administration up to 42 days postvaccination
Number of Participants With Unsolicited Adverse Events Following V920 Vaccination
The number of participants with unsolicited adverse events following vaccination. These include the following disorders: Blood and lymphatic system disorders, cardiac disorders, ear and labyrinth disorders, eye disorders, gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal disorders, skin and subcutaneous tissue disorders,vascular disorders.
Time frame: From vaccine administration up to day 42 postvaccination
Number of Participants With Serious Adverse Events Following V920 Vaccination
The number of participants with solicited vaccine-related serious adverse events following V920 vaccination.
Time frame: From vaccine administration up to day 365 following vaccination
Geometric Mean Titers Induced by V920
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits. Cohorts 1-5.
Time frame: Day 28 postvaccination
Geometric Mean Titers Induced by V920
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits Only Cohort 5 received 2 doses of vaccine.
Time frame: 28 days after LAST (second) dose of vaccine
| Milestone | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 41 | 10 | 40 | 10 | 41 | 9 | 40 | 10 | 40 | 10 |
| Completed | 40 | 9 | 40 | 9 | 41 | 9 | 40 | 10 | 40 | 10 |
| Not completed | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of participants with general solicited local (at the injection site) and systemic adverse events following vaccination will be summarized. Local AES include: pain at injection site, redness at injection site, swelling at injection site Systemic AEs include: fever, arthritis, arthralgia, rash and blisters/vesicular lesions.
| Participants | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Local - injection site erythema | 5 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Local - Injection site pain | 22 | 3 | 20 | 3 | 24 | 1 | 34 | 3 | 30 | 2 |
| Local - Injection site swelling | 4 | 0 | 0 | 1 | 2 | 0 | 4 | 1 | 1 | 1 |
| Systemic - Abdominal pain | 4 | 0 | 5 | 1 | 4 | 1 | 4 | 1 | 8 | 1 |
| Systemic - Arthralgia | 14 | 0 | 16 | 2 | 7 | 1 | 3 | 0 | 10 | 1 |
| Systemic - Blister | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Systemic - Chills | 14 | 0 | 4 | 1 | 8 | 1 | 3 | 0 | 6 | 0 |
| Systemic - Diarrhea | 10 | 1 | 2 | 1 | 2 | 1 | 1 | 0 | 2 | 0 |
| Systemic - Fatigue | 21 | 3 | 18 | 5 | 24 | 1 | 8 | 1 | 20 | 1 |
| Systemic - Feeling hot | 11 | 0 | 7 | 2 | 8 | 1 | 10 | 3 | 15 | 1 |
| Systemic - Headache | 23 | 4 | 21 | 2 | 20 | 2 | 22 | 5 | 23 | 0 |
| Systemic - Hyperhidrosis | 11 | 0 | 1 | 0 | 3 | 1 | 4 | 0 | 7 | 1 |
| Systemic - Joint swelling | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Systemic - Myalgia | 12 | 2 | 8 | 1 | 2 | 0 | 3 | 0 | 10 | 0 |
| Systemic - Nausea | 10 | 1 | 3 | 2 | 3 | 0 | 3 | 0 | 9 | 0 |
| Systemic - Pyrexia | 5 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 1 | 0 |
| Systemic - Rash | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 0 |
The number of participants with solicited systemic adverse events following vaccination that include arthralgia, blister, joint swelling, pyrexia and rash
| Participants | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | 9 | 2 | 15 | 2 | 6 | 0 | 0 | 0 | 6 | 1 |
| Blister | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Joint swelling | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pyrexia | 8 | 0 | 2 | 0 | 1 | 0 | 7 | 0 | 3 | 0 |
| Rash | 0 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 |
The number of participants with unsolicited adverse events following vaccination. These include the following disorders: Blood and lymphatic system disorders, cardiac disorders, ear and labyrinth disorders, eye disorders, gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal disorders, skin and subcutaneous tissue disorders,vascular disorders.
| Participants | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Blood and lymphatic system disorders - Lymphadenopathy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiac disorders - Angina pectoris | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Ear and labyrinth disorders - Cerumen impaction | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Eye disorders - Conjunctivitis allergic | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Eye disorders - Eye irritation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Eye disorders - Eye pain | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gastrointestinal disorders - Abdominal pain | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Gastrointestinal disorders - Abdominal pain upper | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Gastrointestinal disorders - Dental caries | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Gastrointestinal disorders - Diarrhea | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Gastrointestinal disorders - Dyspepsia | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Gastroduodenal ulcer | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Gastrointestinal disorder | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Malpositioned teeth | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Oral papule | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Peptic ulcer | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders - Toothache | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| General disorders and administration site conditions - Chest pain | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions - Fatigue | 6 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions - Ill-defined disorder | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| General disorders and administration site conditions - Injection site induration | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions - Pain | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| General disorders and administration site conditions - Tenderness | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Amoebic dysentery | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Infections and infestations - Bronchitis | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 0 | 1 | 0 |
| Infections and infestations - Conjunctivitis | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 |
| Infections and infestations - Conjunctivitis bacterial | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Infections and infestations - Cutaneous leishmaniasis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Infections and infestations - Cystitis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Furuncle | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Infections and infestations - Gastroenteritis | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Influenza | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Malaria | 5 | 1 | 1 | 0 | 1 | 0 | 4 | 1 | 2 | 0 |
| Infections and infestations - Nasopharyngitis | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Orchitis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Infections and infestations - Otitis media chronic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections and infestations - Parasitic gastroenteritis | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Paronychia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Infections and infestations - Pilonidal disease | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Pneumonia | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Rhinitis | 0 | 0 | 3 | 0 | 4 | 1 | 2 | 0 | 3 | 0 |
| Infections and infestations - Sinobronchitis | 0 | 0 | 1 | 0 | 4 | 1 | 3 | 0 | 1 | 0 |
| Infections and infestations - Tinea pedis | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Tonsillitis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Tooth abscess | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Tooth infection | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Typhoid fever | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Upper respiratory tract infection | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Urinary tract infection | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infections and infestations - Vulvovaginal mycotic infection | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Injury, poisoning and procedural complications -Ankle fracture | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Injury, poisoning and procedural complications - Limb injury | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 |
| Injury, poisoning and procedural complications - Thermal burn | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metabolism and nutrition disorders - Decreased appetite | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders - Back pain | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders - Bursitis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders - Myalgia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders - Pain in extremity | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders - Torticollis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Nervous system disorders - Burning sensation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders - Carpal tunnel syndrome | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders - Dizziness | 0 | 0 | 4 | 0 | 3 | 0 | 1 | 0 | 0 | 1 |
| Nervous system disorders - Headache | 1 | 0 | 3 | 0 | 2 | 0 | 1 | 1 | 3 | 0 |
| Nervous system disorders - Cervicobrachial syndrome | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders - Intercostal neuralgia | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders - Paraesthesia | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders - Sciatica | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Psychiatric disorders - Insomnia | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reproductive system and breast disorders - Breast pain | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reproductive system and breast disorders - Dysmenorrhoea | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Reproductive system and breast disorders - Heavy menstrual bleeding | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reproductive system and breast disorders - Vaginal discharge | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders - Bronchopneumopathy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders - Cough | 2 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 3 | 1 |
| Respiratory, thoracic and mediastinal disorders - Lung disorder | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders - Oropharyngeal pain | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Acne | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Ecchymosis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Hyperhidrosis | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Intertrigo | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Prurigo | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders - Pruritus | 3 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Vascular disorders - Diastolic hypertension | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vascular disorders - Hypertension | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
The number of participants with solicited vaccine-related serious adverse events following V920 vaccination.
| Participants | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events Following V920 Vaccination | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits. Cohorts 1-5.
| Titer | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Geometric Mean Titers Induced by V920 | 1655.0 (1,151.4 to 2,378.9) | 18.1 (8.7 to 37.3) | 1124.6 (821.0 to 1,540.4) | 26.8 (13.8 to 52.0) | 868.8 (679.0 to 1,111.6) | 29.7 (17.5 to 50.2) | 1432.8 (1,091.0 to 1,881.8) | 30.4 (17.6 to 52.4) | 1191.8 (865.7 to 1,640.6) | 43.1 (22.8 to 81.8) |
Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits Only Cohort 5 received 2 doses of vaccine.
| Titer | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|
| Geometric Mean Titers Induced by V920 | 8,416.0 (6,461.9 to 10,961.1) | 40.3 (23.8 to 68.4) |
Collected over 365 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: V920 | 0/40 (0%) | 2/40 (5%) | 25/40 (62.5%) |
| Cohort 1: Placebo | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Cohort 2: V920 | 0/40 (0%) | 0/40 (0%) | 11/40 (27.5%) |
| Cohort 2: Placebo | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Cohort 3: V920 | 0/41 (0%) | 1/41 (2.4%) | 8/41 (19.5%) |
| Cohort 3: Placebo | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Cohort 4: V920 | 0/40 (0%) | 0/40 (0%) | 20/40 (50%) |
| Cohort 4: Placebo | 0/10 (0%) | 1/10 (10%) | 4/10 (40%) |
| Cohort 5: V920 | 0/40 (0%) | 0/40 (0%) | 13/40 (32.5%) |
| Cohort 5: Placebo | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| MalariaInfections and infestations | 1/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 1/10 | 0/40 | 0/10 |
| Hepatitis toxicHepatobiliary disorders | 1/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| ErysipelasInfections and infestations | 1/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| ThrombophlebitisVascular disorders | 1/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| Ankle fractureInjury, poisoning and procedural complications | 0/40 | 0/10 | 0/40 | 0/10 | 1/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| PseudarthrosisMusculoskeletal and connective tissue disorders | 0/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| Event | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 6/40 | 2/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| MalariaInfections and infestations | 5/40 | 1/10 | 0/40 | 0/10 | 0/41 | 0/9 | 4/40 | 1/10 | 2/40 | 0/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/40 | 0/10 | 0/40 | 0/10 | 0/41 | 1/9 | 5/40 | 1/10 | 3/40 | 1/10 |
| RhinitisInfections and infestations | 0/40 | 0/10 | 0/40 | 0/10 | 4/41 | 1/9 | 2/40 | 0/10 | 3/40 | 0/10 |
| SinobronchitisInfections and infestations | 0/40 | 0/10 | 0/40 | 0/10 | 4/41 | 1/9 | 3/40 | 0/10 | 0/40 | 0/10 |
| Back PainMusculoskeletal and connective tissue disorders | 0/40 | 0/10 | 0/40 | 0/10 | 0/41 | 1/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| BronchopneumopathyRespiratory, thoracic and mediastinal disorders | 0/40 | 0/10 | 0/40 | 0/10 | 0/41 | 1/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 4/40 | 0/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 1/10 |
| NasopharyngitisInfections and infestations | 3/40 | 1/10 | 0/40 | 0/10 | 0/41 | 0/9 | 0/40 | 0/10 | 0/40 | 0/10 |
| BronchitisInfections and infestations | 0/40 | 1/10 | 0/40 | 0/10 | 0/41 | 0/9 | 2/40 | 0/10 | 0/40 | 0/10 |
| Age, Categorical(Participants) | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 10 | 12 | 3 | 65 |
| Between 18 and 65 years | 40 | 10 | 39 | 10 | 41 | 9 | 0 | 0 | 28 | 7 | 184 |
| >=65 years | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Age, Continuous(years) | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.1 ± 8.0 | 48.9 ± 8.6 | 48.1 ± 8.3 | 49.9 ± 7 | 46.6 ± 11.1 | 44.1 ± 8.8 | 15 ± 1.5 | 14.5 ± 1.4 | 33.1 ± 15.2 | 33.8 ± 19 | 44 ± 16.7 |
| Sex: Female, Male(Participants) | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 6 | 24 | 7 | 18 | 6 | 20 | 7 | 21 | 4 | 130 |
| Male | 24 | 4 | 16 | 3 | 23 | 3 | 20 | 3 | 19 | 6 | 121 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — Black or African American | 21 | 5 | 39 | 10 | 41 | 9 | 40 | 10 | 40 | 10 | 225 |
| Race — Multiple - Asian, White | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — White | 20 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 |
| Region of Enrollment(Participants) | Cohort 1: V920 | Cohort 1: Placebo | Cohort 2: V920 | Cohort 2: Placebo | Cohort 3: V920 | Cohort 3: Placebo | Cohort 4: V920 | Cohort 4: Placebo | Cohort 5: V920 | Cohort 5: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 20 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 |
| Burkina Faso | 12 | 3 | 23 | 6 | 25 | 6 | 38 | 9 | 24 | 6 | 152 |
| Senegal | 9 | 2 | 16 | 4 | 16 | 3 | 2 | 1 | 16 | 4 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Mar 2023, 67 months.
Results were first posted in Jan 2026, 2 years 10 months after primary completion.
Of 13 phase 2 interventional studies under Hemorrhagic Fever, Ebola, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 39. This study's 67 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: V920
Canadian Immunization Research Network